

REMARKS

Amendments to the specification:

Amendments to the specification are indicated in red for the convenience of the Examiner.

Amendments (1) and (2):

In the name and the formula of the compound of Example 52A, the hydroxyl group of the chain and the methyl group at the 1-N of the core ring were inadvertently omitted. It is obvious that these groups must be present as this compound is prepared from the compound of Example 40A and is subsequently further reacted to the compound of Example 53A, both of which have these substituents in the respective indicated positions.

Amendment (3):

The name of the compound has been corrected to change (2S) to (2R) and to insert "-9-methyl-" as indicated to conform the name of the compound with the formula given at the top of page 108.

Amendment (4)

Example 7 erroneously refers to the compound of Example 40A as its starting material. Inspection of the compound of Example 40A demonstrates that this is the incorrect starting material as the compound of Example 40A has an additional hydroxyl group not present in the compound of Example 7. The compound of Example 47A is identical to that of Example 40A but does not have the extra hydroxyl group and obviously represents the correct starting material for preparation of the compound of Example 7. Therefore, Example 40A has been corrected to Example 47A in the text of Example 7 as indicated.

Amendments to the claims:

By way of this Preliminary Amendment claims 1-15, 17, and 19-20 are pending in this application. Claims 4-14, 17, and 20 have been amended to recast improper multiple dependencies.

Entry of the foregoing amendments is respectfully requested.

The Commissioner is authorized to charge any fees required as a result of this Preliminary Amendment to Deposit Account 13-3372. A duplicate of this sheet is enclosed.

If the Examiner believes that a conversation with Applicants' attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

A handwritten signature in black ink that reads "Barbara A. Shimei". The signature is written in a cursive style with a large, stylized 'B' and 'S'.

Barbara A. Shimei
Reg. No. 29,862
Attorney for Applicants
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Phone: (203) 812-2786
Fax: (203) 812-6459